NLS Cash And Short Term Investments vs Total Stockholder Equity Analysis

NLSPW Stock  USD 0.01  0  27.27%   
NLS Pharmaceutics financial indicator trend analysis is infinitely more than just investigating NLS Pharmaceutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NLS Pharmaceutics is a good investment. Please check the relationship between NLS Pharmaceutics Cash And Short Term Investments and its Total Stockholder Equity accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NLS Pharmaceutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

Cash And Short Term Investments vs Total Stockholder Equity

Cash And Short Term Investments vs Total Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NLS Pharmaceutics Cash And Short Term Investments account and Total Stockholder Equity. At this time, the significance of the direction appears to have almost identical trend.
The correlation between NLS Pharmaceutics' Cash And Short Term Investments and Total Stockholder Equity is 0.92. Overlapping area represents the amount of variation of Cash And Short Term Investments that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of NLS Pharmaceutics AG, assuming nothing else is changed. The correlation between historical values of NLS Pharmaceutics' Cash And Short Term Investments and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Short Term Investments of NLS Pharmaceutics AG are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Cash And Short Term Investments i.e., NLS Pharmaceutics' Cash And Short Term Investments and Total Stockholder Equity go up and down completely randomly.

Correlation Coefficient

0.92
Relationship DirectionPositive 
Relationship StrengthVery Strong

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of NLS Pharmaceutics balance sheet. This account contains NLS Pharmaceutics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by NLS Pharmaceutics AG fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.
Most indicators from NLS Pharmaceutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NLS Pharmaceutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NLS Pharmaceutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
At this time, NLS Pharmaceutics' Selling General Administrative is fairly stable compared to the past year. Enterprise Value is likely to climb to about 1.1 B in 2024, whereas Issuance Of Capital Stock is likely to drop 0.00 in 2024.

NLS Pharmaceutics fundamental ratios Correlations

-0.330.08-0.040.89-0.78-0.460.070.96-0.25-0.25-0.330.960.22-0.340.30.140.62-0.630.420.990.610.530.13-0.310.46
-0.33-0.82-0.81-0.40.840.82-0.87-0.13-0.4-0.371.0-0.13-0.50.99-0.97-0.55-0.820.670.66-0.260.45-0.7-0.70.91-0.8
0.08-0.820.990.03-0.56-0.80.99-0.110.520.51-0.83-0.110.56-0.830.870.610.76-0.15-0.790.02-0.680.680.45-0.860.86
-0.04-0.810.99-0.05-0.49-0.730.99-0.230.590.58-0.83-0.230.5-0.820.870.570.68-0.13-0.86-0.11-0.760.60.49-0.850.81
0.89-0.40.03-0.05-0.82-0.310.060.92-0.15-0.17-0.390.92-0.03-0.420.4-0.090.57-0.730.420.890.630.320.39-0.320.39
-0.780.84-0.56-0.49-0.820.74-0.58-0.65-0.14-0.110.84-0.65-0.360.84-0.82-0.35-0.870.810.15-0.73-0.1-0.69-0.590.76-0.77
-0.460.82-0.8-0.73-0.310.74-0.79-0.240.00.010.82-0.24-0.860.81-0.8-0.86-0.930.50.54-0.440.35-0.98-0.190.71-0.82
0.07-0.870.990.990.06-0.58-0.79-0.120.550.53-0.88-0.120.53-0.870.910.590.75-0.22-0.820.0-0.690.650.53-0.880.85
0.96-0.13-0.11-0.230.92-0.65-0.24-0.12-0.32-0.32-0.141.00.01-0.150.14-0.090.47-0.520.620.970.780.320.08-0.120.29
-0.25-0.40.520.59-0.15-0.140.00.55-0.321.0-0.43-0.32-0.32-0.420.43-0.210.00.07-0.54-0.35-0.56-0.160.7-0.670.39
-0.25-0.370.510.58-0.17-0.110.010.53-0.321.0-0.4-0.32-0.32-0.390.4-0.21-0.010.1-0.53-0.35-0.55-0.160.67-0.650.38
-0.331.0-0.83-0.83-0.390.840.82-0.88-0.14-0.43-0.4-0.14-0.491.0-0.98-0.54-0.820.660.66-0.260.46-0.69-0.690.93-0.82
0.96-0.13-0.11-0.230.92-0.65-0.24-0.121.0-0.32-0.32-0.140.01-0.150.14-0.090.47-0.520.620.970.780.320.08-0.120.29
0.22-0.50.560.5-0.03-0.36-0.860.530.01-0.32-0.32-0.490.01-0.460.460.980.68-0.25-0.490.23-0.380.91-0.23-0.320.5
-0.340.99-0.83-0.82-0.420.840.81-0.87-0.15-0.42-0.391.0-0.15-0.46-0.99-0.51-0.830.660.64-0.270.44-0.68-0.690.92-0.82
0.3-0.970.870.870.4-0.82-0.80.910.140.430.4-0.980.140.46-0.990.510.85-0.56-0.650.24-0.440.670.68-0.910.85
0.14-0.550.610.57-0.09-0.35-0.860.59-0.09-0.21-0.21-0.54-0.090.98-0.510.510.66-0.23-0.590.14-0.480.87-0.18-0.40.56
0.62-0.820.760.680.57-0.87-0.930.750.470.0-0.01-0.820.470.68-0.830.850.66-0.55-0.340.59-0.130.890.31-0.710.86
-0.630.67-0.15-0.13-0.730.810.5-0.22-0.520.070.10.66-0.52-0.250.66-0.56-0.23-0.550.05-0.61-0.18-0.47-0.50.48-0.36
0.420.66-0.79-0.860.420.150.54-0.820.62-0.54-0.530.660.62-0.490.64-0.65-0.59-0.340.050.480.96-0.4-0.380.65-0.49
0.99-0.260.02-0.110.89-0.73-0.440.00.97-0.35-0.35-0.260.970.23-0.270.240.140.59-0.610.480.660.520.05-0.220.4
0.610.45-0.68-0.760.63-0.10.35-0.690.78-0.56-0.550.460.78-0.380.44-0.44-0.48-0.13-0.180.960.66-0.23-0.230.48-0.32
0.53-0.70.680.60.32-0.69-0.980.650.32-0.16-0.16-0.690.320.91-0.680.670.870.89-0.47-0.40.52-0.230.03-0.570.73
0.13-0.70.450.490.39-0.59-0.190.530.080.70.67-0.690.08-0.23-0.690.68-0.180.31-0.5-0.380.05-0.230.03-0.720.39
-0.310.91-0.86-0.85-0.320.760.71-0.88-0.12-0.67-0.650.93-0.12-0.320.92-0.91-0.4-0.710.480.65-0.220.48-0.57-0.72-0.88
0.46-0.80.860.810.39-0.77-0.820.850.290.390.38-0.820.290.5-0.820.850.560.86-0.36-0.490.4-0.320.730.39-0.88
Click cells to compare fundamentals

NLS Pharmaceutics Account Relationship Matchups

NLS Pharmaceutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets696.4K1.2M5.8M9.3M1.8M3.3M
Short Long Term Debt Total7.1M842.1K2.1M1.6M1.5M1.4M
Other Current Liab835.7K1.4M666.4K986.4K1.7M1.0M
Total Current Liabilities4.0M7.2M2.4M3.4M7.9M4.5M
Total Stockholder Equity(6.2M)(9.0M)542.4K3.3M(8.8M)(9.3M)
Net Debt621.9K2.0M(5.4M)(8.9M)736.1K772.9K
Retained Earnings(26.9M)(29.8M)(41.7M)(58.2M)(70.4M)(66.9M)
Accounts Payable2.5M4.0M1.7M2.4M4.6M2.7M
Cash220.3K93.7K5.4M8.9M897.7K852.8K
Non Current Assets Total314.7K1.0M41.6K30.2K23.6K22.4K
Non Currrent Assets Other260.2K946.9K12.0K12.1K16.9K16.0K
Cash And Short Term Investments220.3K93.7K5.4M8.9M897.7K852.8K
Common Stock Shares Outstanding11.1M4.8M14.7M19.7M38.2M40.1M
Liabilities And Stockholders Equity696.4K1.2M5.8M9.3M1.8M3.3M
Non Current Liabilities Total2.8M3.0M2.8M2.6M2.8M3.4M
Other Current Assets86.1K14.4K292.0K191.0K914.7K960.5K
Other Stockholder Equity20.6M20.6M42.1M60.9M61.0M35.5M
Total Liab6.9M10.2M5.2M6.0M10.7M6.6M
Net Invested Capital(5.3M)(6.9M)542.4K3.3M(7.2M)(6.8M)
Total Current Assets381.7K196.7K5.7M9.2M1.8M3.1M
Accumulated Other Comprehensive Income(18.7K)(19.4K)(151.7K)(50.8K)(158.1K)(150.2K)
Net Working Capital(3.7M)(7.0M)3.3M5.9M(6.1M)(5.8M)
Net Receivables75.4K61.2K38.6K41.2K10.7K10.1K
Inventory(33.6K)(61.2K)(38.6K)(41.2K)(37.1K)(39.0K)
Short Term Debt690.1K1.8M2.5B1.6M1.9M1.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NLS Stock Analysis

When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.